ClinicalTrials.gg
RecruitingNCT07641088Updated Nov 16, 2026

Zishen Yutai Pill for Patients With Recurrent Implantation Failure

An interventional study of Zishen Yutai Pill and Placebo in Recurrent Implantation Failure, sponsored by Peking University Third Hospital. Recruiting at 13 sites in China. Open to female participants aged 20 Years to 43 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
878
Allocation
Randomized
Ages
20 Years to 43 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to evaluate the efficacy of Zishen Yutai Pill (ZYP) on pregnancy outcomes following embryo transfer and its safety in patients with recurrent implantation failure. The main question it aims to answer is whether ZYP can improve live birth rate in participant's frozen embryo transfer (FET) cycles.

Researchers will compare ZYP to a placebo (a look-alike substance with similar characteristics to ZYP) to see if it works to improve pregnancy outcomes.

Participants will:

  1. Start to receive ZYP or placebo (5g per time, 3 times daily) within the first 5 days of their initial menstrual cycle, and will undergo FET in the following cycle. The medication will be taken without interruption till the day of pregnancy test (2 weeks after embryo transfer). Patients with positive results in β-HCG test will continue to take the drug until clinical pregnancy confirmation by ultrasound three weeks later. For those with a negative β-HCG result, the intervention will be stopped.
  2. Baseline visit will be conducted on days 2-4 of the participant's first menstrual cycle. Subsequent clinic visits will follow the standard protocol for FET cycle, as outlined below:

Visit 1 (days 2-4 of the second menstrual cycle); Visit 2 (day of ovulation or day of endometrial transformation); Visit 3 (day of embryo transfer); Visit 4 (2 weeks after embryo transfer); Visit 5 (5 weeks after embryo transfer). Follow-up is scheduled at 10 weeks after embryo transfer (Visit 6) and after delivery (Visit 7), and these can be conducted remotely.

02

Conditions studied

  • Recurrent Implantation Failure

Keywords

  • traditional Chinese medicine
  • Zishen Yutai pill
  • recurrent implantation failure
  • frozen-thawed embryo transfer
  • randomized controlled trial
03

In context

Lead sponsor

Peking University Third Hospital is the lead sponsor of 755 studies on the registry; 275 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 43 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the diagnostic criteria for recurrent implantation failure;
  2. Aged between 20-40 years old (inclusive) when oocytes were retrieved, and \<43 at enrollment;
  3. Have at least 1 good-quality embryo for transfer;
  4. Intend to undergo frozen-thawed embryo transfer;
  5. Voluntary participation and signed .

Exclusion criteria

Exclusion Criteria:

  1. Concomitant unresolved intrauterine lesions (e.g., intrauterine adhesions grade III-IV, endometrial polyps ≥1 cm, acute endometritis), endometriosis (ASRM stage ≥III), or adenomyosis (uterine volume ≥8 weeks of gestation) that affect embryo implantation;
  2. Intend to undergo FET after preimplantation genetic testing (PGT), including aneuploidy screening (PGT-A), monogenic disease testing (PGT-M), chromosomal structural rearrangement testing (PGT-SR);
  3. Thin endometrium (\<7 mm) before enrollment;
  4. Concomitant severe genital malformations or genital neoplasms;
  5. to estrogen and progestogen (e.g., history of breast cancer);
  6. Presence of medical contraindications to assisted reproductive technology, including that either partner has a severe psychiatric disorder, acute genitourinary tract infection, sexually transmitted disease, serious deleterious habit (e.g., drug abuse), or teratogenic exposure to radiation, toxic agent or medication that still under effect; or genetic diseases specified in the Law of the People's Republic of China on Maternal and Infant Health Care for which childbearing and PGT are contraindicated; or severe somatic diseases incompatible with pregnancy; or chromosomal abnormalities;
  7. (AST) or alanine aminotransferase (ALT) >1.5 × the (ULN), or serum creatinine (Scr) > ULN;
  8. Presence of poorly controlled severe systemic diseases, including cardiovascular, digestive, endocrine, and diseases (e.g., antiphospholipid syndrome, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis);
  9. Use of traditional Chinese medicines with similar functions and indications to ZYP within 1 month before screening that may affect treatment efficacy. Chinese patent medicines such as Tiaojing Cuyun Pills, Kuntai Capsules, Peikun Pills, Qilin Pills, Jinfeng Pills, Gushen Antai Pills, and Chinese herbal decoctions containing Cuscutae Semen, Dipsaci Radix, Taxilli Herba, and Asini Corii Colla with kidney-tonifying and spleen-strengthening effects;
  10. Allergy to any component of the study drugs;
  11. Participated in another interventional trials within 1 month prior to enrollment;
  12. Deemed unsuitable for this study by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
878 participants (estimated)

Study arms

  • Experimental
    ZYP group

    Zishen Yutai Pill, 5g per time, three times daily

    Drug: Zishen Yutai Pill

  • Placebo comparator
    Placebo group

    Placebo, 5g per time, three times daily

    Drug: Placebo

Interventions

  • DrugZishen Yutai Pill

    Eligible participants start to receive ZYP within the first 5 days of their initial menstrual cycle, and will undergo frozen-thawed embryo transfer (FET) in the following cycle. The medication will be taken without interruption till the day of pregnancy test (two weeks after embryo transfer). Patients with positive results in β-HCG test will continue to take the drug until clinical pregnancy confirmation by ultrasound three weeks later. For those with negative β-HCG results, the intervention will be stopped.

  • DrugPlacebo

    Eligible participants start to receive placebo within the first 5 days of their initial menstrual cycle, and will undergo frozen-thawed embryo transfer (FET) in the following cycle. The medication will be taken without interruption till the day of pregnancy test (two weeks after embryo transfer). Patients with positive results in β-HCG test will continue to take the drug until clinical pregnancy confirmation by ultrasound three weeks later. For those with negative β-HCG results, the intervention will be stopped.

06

What researchers measure

Primary outcomes

  1. Live birth rate

    Live birth is defined as delivery of any viable infants after 28 weeks of gestation.

    Time frame: About 40 weeks after embryo transfer, up to a maximum duration of 52 weeks after enrollment.

Secondary outcomes

  1. Endometrial thickness (ovulation day/endometrial transformation day)

    Natural cycle and hormone replacement therapy (HRT) cycle are two endometrial preparation methods before frozen embryo transfer.

    Time frame: On the day of ovulation (natural cycle) or on the day of endometrial transformation (HRT cycle), about 6 weeks after enrollment.

  2. Endometrial pattern (ovulation day/endometrial transformation day)

    Natural cycle and hormone replacement therapy (HRT) cycle are two endometrial preparation methods before frozen embryo transfer.

    Time frame: On the day of ovulation (natural cycle) or on the day of endometrial transformation (HRT cycle), about 6 weeks after enrollment.

  3. Endometrial thickness (embryo transfer day)

    Time frame: On the day of embryo transfer, about 6-7 weeks after enrollment.

  4. Endometrial pattern (embryo transfer day)

    Time frame: On the day of embryo transfer, about 6-7 weeks after enrollment.

  5. β-HCG positive rate

    Serum β-HCG level ≥ 20 IU/L at 2 weeks after embryo transfer is defined as positive.

    Time frame: At 2 weeks after embryo transfer, about 8 weeks after enrollment.

  6. Implantation rate

    Implantation rate is defined as the number of gestational sacs per the number of embryos transferred.

    Time frame: At 5 weeks after embryo transfer, about 11 weeks after enrollment.

  7. Clinical pregnancy rate

    Clinical pregnancy is defined as the presence of intrauterine gestation sac under transvaginal ultrasonography.

    Time frame: At 5 weeks after embryo transfer, about 11 weeks after enrollment.

  8. Ongoing pregnancy rate

    Ongoing pregnancy is defined as pregnancy with live fetus beyond 10 weeks after embryo transfer (approximately 12 weeks of gestation).

    Time frame: About 40 weeks after embryo transfer, up to a maximum duration of 52 weeks after enrollment.

  9. Biochemical pregnancy loss rate

    Biochemical pregnancy loss is defined as a positive serum β-HCG test with no evidence of a gestational sac on subsequent ultrasound.

    Time frame: At 5 weeks after embryo transfer, about 11 weeks after enrollment.

  10. Clinical pregnancy loss rate

    Clinical pregnancy loss is defined as the failure of a confirmed clinical pregnancy to progress to live birth.

    Time frame: About 40 weeks after embryo transfer, up to a maximum duration of 52 weeks after enrollment.

  11. Gestational age at delivery

    Time frame: About 40 weeks after embryo transfer, up to a maximum duration of 52 weeks after enrollment.

  12. Birthweight

    Time frame: About 40 weeks after embryo transfer, up to a maximum duration of 52 weeks after enrollment.

  13. Rate of adverse events

    Time frame: About 40 weeks after embryo transfer, up to a maximum duration of 52 weeks after enrollment.

07

Study locations

7 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data will be provided as supplementary materials upon publication in a peer-reviewed journal.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be shared within two years after publication in a peer-reviewed journal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Dec 2029, 37 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jun 11, 2026
StartActual
Nov 4, 2026was Jul 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
13 sites changed recruiting status (7 now recruiting, 6 now not yet recruiting)
Show 13 sites
  • The First Affiliated Hospital of University of Science and Technology of China · Hefei, Chinano status→Not yet recruiting
  • Peking University Third Hospital · Beijing, Chinano status→Recruiting
  • Peking University People's Hospital · Beijing, Chinano status→Recruiting
  • Nanfang Hospital, Southern Medical University · Guangzhou, Chinano status→Not yet recruiting
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Chinano status→Recruiting
  • The Second Hospital of Hebei Medical University · Shijiazhuang, Chinano status→Recruiting
  • The Second Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Recruiting
  • Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
  • Jiangsu Province Hospital · Nanjing, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Xi'an Jiao Tong University · Xi'an, Chinano status→Recruiting
  • Shanghai Ninth People's Hospital · Shanghai, Chinano status→Not yet recruiting
  • Sichuan Jinxin Xinan Women and Children's Hospital (Bisheng) · Chengdu, Chinano status→Recruiting
  • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Chinano status→Not yet recruiting
Nov 16, 2026
Start date
Jul 1, 2026→Nov 4, 2026 (actual)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    13 sites changed recruiting status (7 now recruiting, 6 now not yet recruiting)
    Show 13 sites
    • The First Affiliated Hospital of University of Science and Technology of China · Hefei, Chinano status→Not yet recruiting
    • Peking University Third Hospital · Beijing, Chinano status→Recruiting
    • Peking University People's Hospital · Beijing, Chinano status→Recruiting
    • Nanfang Hospital, Southern Medical University · Guangzhou, Chinano status→Not yet recruiting
    • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Chinano status→Recruiting
    • The Second Hospital of Hebei Medical University · Shijiazhuang, Chinano status→Recruiting
    • The Second Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Recruiting
    • Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
    • Jiangsu Province Hospital · Nanjing, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Xi'an Jiao Tong University · Xi'an, Chinano status→Recruiting
    • Shanghai Ninth People's Hospital · Shanghai, Chinano status→Not yet recruiting
    • Sichuan Jinxin Xinan Women and Children's Hospital (Bisheng) · Chengdu, Chinano status→Recruiting
    • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Chinano status→Not yet recruiting
    Start date Jul 1, 2026→Nov 4, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07641088
Responsible party
Li Rong (Vice President of Peking University Third Hospital, Director of the Department of Reproductive Medicine, Deputy Chair of the Department of Obstetrics and Gynecology, Peking University, Peking University Third Hospital) — Principal investigator
First posted
Jun 11, 2026
Start date
Nov 4, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Rong Li
Contact
roseli001@sina.com
+86 13701085402
Xiaoyu Long
Contact
doralonger@hotmail.com
+86-010-82264816
Rong Li, MD, PhD
principal investigator · Peking University Third Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion